Announcements Trials

Browse Landscape

Phase

Phase 2 96 Phase 1 35 Phase 1/2 21 Phase 3 12 Phase EARLY_PHASE1 6 Phase NA 5 Phase 4 3 Phase 2/3 1

Status

Sponsor Class

OTHER 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hormone Receptor Positive HER-2 Negative Breast Cancer 1

Interventions

Cisplatin 54 Cyclophosphamide 42 Fluorouracil 41 Oxaliplatin 36 Capecitabine 35 Docetaxel 34 Gemcitabine 32 Drug Therapy 32 Radiotherapy 31 Paclitaxel 25 Dexamethasone 23 Carboplatin 23 Leucovorin 21 Etoposide 17 Doxorubicin 17 Cytarabine 17 apatinib 16 Methotrexate 16 Magnetic Resonance Spectroscopy 14 Radiation 13 Epirubicin 13 Busulfan 13 Bevacizumab 13 Surgical Procedures, Operative 12 Neoadjuvant Therapy 12 Letrozole 12 Decitabine 12 Saline Solution 11 Irinotecan 11 venetoclax 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × palbociclib × Clear all

NCT02692755 2021-09-28

PALINA

Georgetown University

Phase 2/3 Completed

35 enrolled 12 charts

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡